CHS-0214 Phase III trial

A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222570

Enrollment

620

Registered

2014-07-29

Start date

2014-07-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

investigational material(s) Generic name etc : CHS-0214 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigati

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Have a diagnosis of RA

Exclusion criteria

Exclusion criteria: Diagnosis of other rheumatic disease

Design outcomes

Primary

Measure	Time frame
Efficacy (ACR20), Safety ACR core set	—

Secondary

Measure	Time frame
Efficacy (ACR50, 70) ACR core set	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026